MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.aohep.2026.102184

Медицинская библиотека · Annals of hepatology · 2026

Screening and management for portal hypertension in hepatocellular carcinoma: A nationwide survey in China.

Li Xueyan, Chen Huiyu, Zhang Qingqing, Wang Shaotong, Wang Youping, Chen Yixuan, Song Jun, Chen Mingkai

СтатьяПеревод в очереди

Аннотация

INTRODUCTION AND

OBJECTIVES

Hepatocellular carcinoma (HCC) and portal hypertension (PHT) are two common complications of cirrhosis that often co-exist and significantly affect patient prognosis, yet global management varies widely. This study evaluated Chinese physicians' perspectives on PHT screening and management in HCC.

MATERIALS AND

METHODS

An online questionnaire survey was distributed to hepatologists, gastroenterologists, gastrointestinal oncologists, and hepatobiliary surgeons across 132 hospitals in 16 provinces throughout China from March 1, 2024, to June 30, 2024. The questionnaire comprised 57 items across four sections. This study was approved by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (No. 2024-0365) and registered at the Chinese Clinical Trial Registry (ChiCTR2400084630).

RESULTS

Overall, 1,584 participants responded to the questionnaire. The reported PHT screening rate in HCC patients was 82.6%. Imaging was the most common modality (50.5%), followed by endoscopy (30.8%). However, adherence to the Baveno VI/VII consensus was only 28%. Complications of PHT, including gastrointestinal bleeding and ascites, significantly affected physicians' screening practices. The primary and secondary prophylaxis strategies for PHT generally comply with the Baveno VII consensus. A history of acute variceal bleeding within 6 months significantly reduced the preference for atezolizumab and bevacizumab therapy (19.6% vs. 32.9%, P<0.001). In cases of acute variceal bleeding during atezolizumab-bevacizumab therapy, 79.5% of the physicians recommended permanent discontinuation of bevacizumab, whereas 20.5% advocated continuation upon achieving hemostasis.

CONCLUSIONS

Substantial heterogeneity exists in the management of PHT among HCC patients in China, highlighting the need for targeted multidisciplinary education to standardize care and improve patient outcomes.

Для цитирования: Li Xueyan, Chen Huiyu, Zhang Qingqing, Wang Shaotong, Wang Youping, Chen Yixuan, Song Jun, Chen Mingkai. Screening and management for portal hypertension in hepatocellular carcinoma: A nationwide survey in China.. Annals of hepatology. 2026. DOI: 10.1016/j.aohep.2026.102184.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.